GLIVEC 400MG
IMATINIB
Reimbursement base
23.400,00 MAD
Active substance
IMATINIB
What is this medicine?
Imatinib mesylate is a kinase inhibitor indicated for the treatment of various types of leukemia, myeloproliferative diseases, and specific stromal tumors.
Verified summary
IMATINIB, COMPRIME PELLICULE, 400 MG, 1 BOITE 30 COMPRIME PELLICULE
Common uses
Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML),Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL),Myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements,Aggressive systemic mastocytosis (ASM),Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL),Unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP),Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST),Adjuvant treatment following resection of Kit (CD117) positive GIST
Class
kinase inhibitor
Hospital price
23.400,00 MAD
Strength
400 MG
Form
COMPRIME PELLICULE
Presentation
1 BOITE 30 COMPRIME PELLICULE
Type
P
This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.
Price history
Reference price recorded since 2017-12-18: 0,00 MAD
Available presentations and strengths
Medicines with the same active substance
CEMIVIL 100 MG
100 MG · Boite de 30
848,00 MAD
IMATINIB ZENITH 100 MG
100 MG · Boite de 30
963,00 MAD
CEMIVIL 400 MG
400 MG · Boite de 30
2.010,00 MAD
IMATINIB ZENITH 400 MG
400 MG · Boite de 30
3.016,00 MAD
IMATINIB COOPER 100 MG
100 MG · Boîte de 120
3.500,00 MAD
IMATEC 100 MG
100 MG · Boîte de 120
3.503,00 MAD
IMATEC
100 MG · 1 BOITE 120 GELULE
3.800,00 MAD
IMATINIB COOPER
100 MG · 1 BOITE 120 GELULE
3.800,00 MAD